To
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai - 400001.

Date: 14/11/2026

Scrip Code: 544759, Scrip ID: GLPL,

Subject: Outcome of Board Meeting dated 14th November, 2026 pursuant to Reg 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 & Submission of Un-audited Standalone Financial Results of the Company for the half year ended September 30, 2026.

Dear Sir/Madam,

We wish to inform you that in compliance with the provisions of Regulation 33 read with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the Board of Directors at their meeting held today, i.e. have inter alia approved the following:

The Un-audited Standalone Financial Results of the Company for the half year ended September 30, 2026 together with Statement of Assets and Liabilities.

The Board Meeting commenced at 04:00 P.M. and concluded at 04:50 P.M.

The aforesaid results are also being disseminated on company's website at https://www.goldlinepharma.in/FinancialResults.html

You are requested to kindly take the information on your record.

Thanking you,

Yours faithfully,
For Goldline Pharmaceutical Limited

Ruchi Sanket Modi
Digitally signed by Ruchi Sanket Modi
Date: 2026.11.14 19:24:56 +05'30'

Ruchi Sanket Modi
Company Secretary cum Compliance Officer

B. SHROFF & Co.
CHARTERED ACCOUNTANTS

CA. Nilesh Tiwari
(Partner) B.SC., FCA, DISA
9970854770
ca.nileshtiwari@gmail.com

Independent Auditor's Limited Review Report on Half Yearly and Year to Date Financial Results of Goldline Pharmaceutical Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To
The Board of Directors,
Goldline Pharmaceutical Limited
Nagpur, Maharashtra

We have reviewed the accompanying statement of unaudited financial results of **Goldline Pharmaceutical Limited** for the half year ended **30th September 2026** being prepared and submitted by the company pursuant to the requirement of the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended ("SEBI LODR Regulations"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on this financial result based on our review.

We conducted our review of the statements in accordance with the Standard on Review Engagement (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India (ICAI).

A review of interim financial information consists primarily of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with *Standards on Auditing* (SAs) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B SHROFF & CO.
Chartered Accountants
Firm Reg. No. 006514W

B SHROFF & CO. NAGPUR CHARTERED ACCOUNTANTS

CA Nilesh Tiwari
Partner
M.No.130513
UDIN : 26130513XRDYNU8889

Place: Nagpur
Date: 14th November 2026

GOLDLINE PHARMACEUTICAL LIMITED

CIN:L51397MH2004PLC147806

103, F-1,LEELA APARTMENTS, SHILPA HSG SOCIETY,NEAR SAPTAGIRI NAGAR, SHANIDHAM, NARENDRA NAGAR, NAGPUR, MAHARASHTRA, INDIA, 440015

BALANCE SHEET AS AT 30TH SEPT, 2026

(Rs. In Lacs)

	Particulars	Half Year Ended		Year Ended
		As At Sept 30, 2026	As At Sept 30, 2025	As At March 31, 2026
		Unaudited	Audited	Audited
	EQUITY AND LIABILITIES			
1	**Shareholder's funds**			
	(a) Share Capital	1,140.70	870.70	870.70
	(b) Reserves and surplus	1,452.85	299.80	554.26
		2,593.55	**1,170.50**	**1,424.96**
2	**Share Application Money Pending Allotment**			-
3	**Non-current liabilities**			
	(a) Long-term borrowings	66.65	351.47	146.32
	(b) Deferred Tax Liabilities (Net)	-	12.11	-
	(c) Other Long Term Liabilities	22.00	22.00	22.00
	(d) Long-term provisions	90.38	68.22	82.45
		179.03	**453.81**	**250.77**
4	**Current liabilities**			
	(a) Short-term borrowings		660.28	769.85
	(b) Trade payables		-	
	(i) Total outstanding dues of micro enterprises and small enterprises	98.62	132.18	93.71
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	99.34	81.60	91.36
	(c) Other current liabilities	146.94	75.41	112.37
	(d) Short-term provisions	213.24	146.29	144.08
		558.14	**1,095.76**	**1,211.36**
	TOTAL	**3,330.72**	**2,720.07**	**2,887.09**
	ASSETS			
1	**Non-current assets**			
	(a) Property, Plant And Equipment & Intangible Assets			
	(i) Property, Plant And Equipment	254.39	274.63	264.91
	(ii) Intangible Assets	5.60	5.50	5.60
	(iii) Capital WIP			-
	(iv) Tangible assets under development			-
	(b) Non-current investments	2.50	2.50	2.50
	(c) Defered Tax Asset (net)	42.97	-	7.68
	(d) Long-term loans and advances	1.56	1.56	1.56
	(e) Other Non Currrent Assets			-
	TOTAL (1)	**307.02**	**284.19**	**282.25**
2	**Current assets**			
	(a) Current investments			-
	(b) Inventories	598.43	732.53	621.22
	(c) Trade receivables	1,853.27	1,273.83	1,612.81
	(d) Cash and cash equivalents	155.52	75.84	59.24
	(e) Short-term loans and advances	242.73	307.46	198.35
	(f) Other Current Assets	173.76	46.22	113.22
	TOTAL (2)	**3,023.71**	**2,435.87**	**2,604.83**
	TOTAL (1+2)	**3,330.72**	**2,720.07**	**2,887.09**

For & on behalf of the Board of Directors of
Goldline Pharmaceutical Limited

Amol Mujumdar
Managing Director
DIN: 01910549

Date : 14-11-2026
Place : Nagpur

GOLDLINE PHARMACEUTICAL LIMITED

CIN:L51397MH2004PLC147806

103, F-1, LEELA APARTMENTS, SHILPA HSG SOCIETY,NEAR SAPTAGIRI NAGAR, SHANIDHAM,
NARENDRA NAGAR, NAGPUR, MAHARASHTRA, INDIA, 440015

STATEMENT OF PROFIT AND LOSS FOR THE HALF YEAR ENDED 30TH SEPT, 2026

(Rs. In Lacs)

	Particulars	Half Year Ended			Year Ended	
		30th Sept 2026	31st March 2026	30th Sept 2025	31st March 2026	31st March 2025
		Unaudited	Audited	Audited	Audited	Audited
I.	**Revenue**					
	Revenue from operations	1,492.50	1,730.55	1,389.21	3,119.76	2,805.57
II.	Other income	-	0.11		0.11	-
III.	**Total Income (I +II)**	**1,492.50**	**1,730.67**	**1,389.21**	**3,119.88**	**2,805.57**
IV.	**Expenses**					
	Cost of materials consumed					-
	Purchases & Direct Expenses	454.05	476.39	586.13	1,062.52	1,008.80
	Changes in Inventories of Finished Goods Work-in-Progress and Stock-in-Trade	22.79	111.31	(54.81) -	56.50 -	71.34 -
	Employee benefits expense	446.67	373.89	333.12	707.01	575.40
	Finance costs	27.92	64.83	66.63	131.46	172.34
	Depreciation & amortisation Expense	11.18	12.32	11.81	24.13	25.03
	Other Expenses	298.38	338.48	261.24	599.72	566.82
	Total expenses	**1,260.99**	**1,377.22**	**1,204.12**	**2,581.34**	**2,419.73**
V.	**Profit before exceptional and extraordinary items and tax (III-IV)**	231.51	353.45	185.09	538.54	385.84
VI.	Exceptional items					-
VII.	**Profit before extraordinary items and tax (V - VI)**	231.51	353.45	185.09	538.54	385.84
VIII.	Extraordinary items					-
IX.	Profit before tax (VII-VIII)	231.51	353.45	185.09	538.54	385.84
X.	**Income for earlier Year**					-
XI.	**Tax expense:**					
	(1) Current tax	61.64	97.10	46.33	143.43	99.14
	(2) Deferred tax Asset / (Liability)	35.28	19.80	3.20	16.60	(3.27)
	(3) Income tax for earlier year					-
XII	**Profit After Tax from continuing operations**	**205.15**	**276.15**	**141.96**	**411.71**	**283.43**
XIII	**Earning per equity Share : (1) Basic & Diluted**	2.31	4.00	1.96	5.97	4.11

For & on behalf of the Board of Directors of
Goldline Pharmaceutical Limited

Amol Mujumdar
Managing Director
DIN: 01910549

Date : 14-11-2026
Palce : Nagpur

GOLDLINE PHARMACEUTICAL LIMITED

CIN-L51397MH2004PLC147806

103, F-1, LEELA APARTMENTS, SHILPA HSG SOCIETY,NEAR SAPTAGIRI NAGAR, SHANIDHAM, NARENDRA NAGAR, NAGPUR, MAHARASHTRA, INDIA, 440015

Statement of Cash Flow

Particulars	Sept 30th , 2026	March 31st , 2026
	Unaudited	Audited
Cash Flow from Operating Activities		
Profit/(Loss) Before Extraordinary Losses & Tax	231.51	538.54
Adjustment for		
Depreciation	11.18	24.13
Finance Cost	27.92	131.46
Non Operating Income	-	0.11
Loss From Sale of Fixed Assets	-	-
Prior Period Adjustments		-
Operating cash flow before working capital changes	**270.62**	**694.24**
Decrease(Increase) in Other Current Assets		
Inventories	22.79	56.50
Trade Receivables	(240.47)	(543.48)
Short Term Loans & Advances	(44.38)	89.11
Other Current Assets	(60.54)	57.27
(Decrease)Increase in Current Liabilities/Non Current Liability		
Trade Payables	12.90	(20.67)
Other Current Liabilities	34.58	29.25
Short term Provisions	8.31	0.91
Other Long term Liability		
Other Long term Provisions	7.93	16.48
Working Capital Change	**(258.89)**	**(314.64)**
Cash flow from Extraordinary items	-	-
Cash generated from operations	**11.73**	**379.60**
Income Tax Paid	0.80	98.14
Cash Flow from Operating activities (A)	**10.93**	**281.46**
Non-Operating Income	-	(0.11)
Purchase of Fixed Assets	(0.66)	(5.67)
Decrease in Depreciation Reserve	-	-
Sale/(Purchase) of Property Plant & Equipment	-	-
Increase/(Decrease) in Long Term Loan & Advances	-	-
Increase in Non Current Investment/Assets	-	-
Net Cash from Investing activities (B)	**(0.66)**	**(5.78)**
Cash Flow from Financing activities:-		
Proceeds from Share Application Money	-	-
Proceeds from Share Capital	270.00	-
Proceeds/(Repayment) from/to Long term borrowings (Net)	(79.66)	(172.95)
Proceeds/(Repayment) from/to Short term borrowings (Net)	(769.85)	(14.32)
Proceeds from security Premium	891.00	-
Finance Cost	(27.92)	(131.46)
Share Issue expenses	(175.88)	
Dividend paid During the year	(21.68)	(21.68)
Net Cash Flow from Financing activities (C)	**86.01**	**(340.41)**
Net Increase in Cash & Cash Equivalents(A+B+C)	**96.28**	**(64.73)**
Cash & Cash Equivalents (Refer Note 18)		
- At the beginning of the year	59.24	123.97
- At the end of the year	**155.52**	**59.24**

For & on behalf of the Board of Directors of
Goldline Pharmaceutical Limited

Amol Mujumdar
Managing Director
DIN: 01910549

Date : 14-11-2026
Place : Nagpur

Goldline Pharmaceutical Limited

Notes to Financial Statements for the year ended 30th September 2026

1. The above financial results have been reviewed and recommended by the Audit Committee meeting held on 14th November 2026 and approved by the Board of Directors of the Company in their respective meetings held on November 14, 2026. The same have been reviewed by the Statutory Auditors of the Company as required under Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.

3. The company is engaged in only one business of marketing and distribution of pharmaceutical products. Hence, no information has been furnished in accordance with AS 17 on "Segment Reporting" issued by the Institute of Chartered Accountants of India.

4. The date of implementation of the Code on Social Security, 2020 ("the Code") relating to employee benefits is yet to be notified by the Government. When implemented, it will impact the contributions by the Company towards benefits such as Provident Fund Gratuity, etc. The Company will assess the impact of the Code and give effect to it in the financial results when the Code and Rules thereunder are notified.

5. The aforesaid Half Yearly Financial Results are also being disseminated on the website of the Company at www.goldlinepharma.in.

6. The figures for the corresponding previous period have been re-grouped / re-arranged / re-classified / re-stated wherever necessary, to make them comparable to the extent possible.

To

The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai - 400001.

Date: 14/11/2026

Scrip Code: 544759, Scrip ID: GLPL,

Subject Declaration on Auditor's Report under Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir,

Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 we hereby declare and confirm that the Auditors Limited Review Report on Un-audited Standalone Financial Results of the Company for the half year ended September 30, 2026 which are being sent herewith are unmodified and without any qualification.

Thanking you,

Yours faithfully,
For Goldline Pharmaceutical Limited

Ruchi Sanket Modi
Digitally signed by Ruchi Sanket Modi
Date: 2026.11.14 19:25:24 +05'30'

Ruchi Sanket Modi
Company Secretary cum Compliance Officer